Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Phase 1
Phase 2
• To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral load of SARS-CoV-2
Phase 3
Cohort 1 (≥18 Years Old, Not Pregnant at Randomization)
• To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo as measured by COVID-19-related hospitalizations or all-cause death
Cohort 2 (<18 Years Old, Not Pregnant at Randomization)
Cohort 3 (Pregnant at Randomization) • To evaluate the safety and tolerability of REGN10933+REGN10987
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other Protocol defined Inclusion/Exclusion criteria apply
Primary purpose
Allocation
Interventional model
Masking
10,078 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal